Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 94
Filtrar
1.
Nefrología (Madrid) ; 43(1): 111-119, ene.-feb. 2023. tab, graf
Artigo em Inglês | IBECS | ID: ibc-215246

RESUMO

Background: We aimed to describe the thiamine status in hospitalized hypervolemic heart failure (HF) and/or renal failure (RF) patients treated with furosemide and to investigate whether there was a difference in furosemide-related thiamine deficiency between patients with RF and HF. Methods: Patients who were diagnosed as hypervolemia and treated with intravenous furosemide (at least 40mg/day) were included in this prospective observational study. Whole blood thiamine concentrations were measured 3 times during hospital follow-up of patients. Results: We evaluated 61 hospitalized hypervolemic patients, of which 22 (36%) were men and 39 (64%) were women, with a mean age of 69.00±10.39 (45–90) years. The baseline and post–hospital admission days 2 and 4 mean thiamine levels were 51.71±20.66ng/ml, 47.64±15.43ng/ml and 43.78±16.20ng/ml, respectively. Thiamine levels of the hypervolemic patients decreased significantly during the hospital stay while furosemide treatment was continuing (p=0.029). There was a significant decrease in thiamine levels in patients who had HF (p=0.026) and also, thiamine was significantly lower in HF patients who had previously used oral furosemide before hospitalization. However, these findings were not present in patients with RF. (AU)


Antecedentes: Nos propusimos describir el estado de la tiamina en pacientes hospitalizados con insuficiencia cardíaca (IC) y/o insuficiencia renal (IR) hipervolémica tratados con furosemida, e investigar si había una diferencia en la deficiencia de tiamina relacionada con la furosemida entre los pacientes con IR y con IC. Métodos: En este estudio observacional prospectivo se incluyeron pacientes con diagnóstico de hipervolemia y tratados con furosemida intravenosa (al menos 40 mg/día). Se midieron las concentraciones de tiamina en sangre total 3 veces durante el seguimiento hospitalario de los pacientes. Resultados: Se evaluaron 61 pacientes hipervolémicos hospitalizados, de los cuales 22 (36%) eran hombres y 39 (64%) eran mujeres, con una edad media de 69,00±10,39 (45-90) años. Los niveles medios de tiamina en la línea de base y tras el ingreso hospitalario en los días 2 y 4 fueron de 51,71±20,66 ng/ml, 47,64±15,43 ng/ml y 43,78±16,20 ng/ml, respectivamente. Los niveles de tiamina de los pacientes hipervolémicos hipervolemia disminuyeron significativamente durante la estancia en el hospital mientras se mantenía el tratamiento con furosemida furosemida (p = 0,029). Hubo una disminución significativa de los niveles de tiamina en los pacientes que tenían IC (p = 0,026) y también, la tiamina fue significativamente menor en los pacientes con IC que habían habían utilizado previamente furosemida oral antes de la hospitalización. Sin embargo, estos hallazgos no se presentes en los pacientes con IC. (AU)


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Insuficiência Cardíaca , Insuficiência Renal , Deficiência de Tiamina , Furosemida/uso terapêutico , Estudos Prospectivos
3.
Med. paliat ; 27(1): 54-57, ene.-mar. 2020. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-194824

RESUMO

Presentamos dos casos clínicos de pacientes con pericarditis constrictiva en insuficiencia cardiaca refractaria a tratamiento diurético combinado y dosis elevadas de furosemida, con disnea de pequeños-mínimos esfuerzos y grandes dificultades para abandonar el hospital por dependencia al tratamiento parenteral. Fueron tratados con infusión continua intravenosa de furosemida mediante infusores elastoméricos. La técnica se mantuvo a largo plazo en domicilio de forma eficaz, con muy buena tolerancia y sin efectos secundarios reseñables


We present two clinical cases about constrictive pericarditis in advanced heart failure refractory to combined diuretic therapy and high dose of furosemide. Patients had small-minimum efforts dyspnea and difficulties to be discharged because of parenteral treatment dependency. They were treated with intravenous continuous furosemide infusion administered by elastomeric pumps. Long-term use at home was effective, well-tolerated and without remarkable secondary effect


Assuntos
Humanos , Masculino , Idoso , Idoso de 80 Anos ou mais , Insuficiência Cardíaca/tratamento farmacológico , Pericardite Constritiva/diagnóstico , Furosemida/administração & dosagem , Infusões Intravenosas/métodos , Terapia por Infusões no Domicílio/instrumentação , Administração Intravenosa/métodos , Dispneia/complicações , Pericardite Constritiva/cirurgia , Acetazolamida/administração & dosagem
10.
Allergol. immunopatol ; 46(6): 585-593, nov.-dic. 2018. graf, ilus, tab
Artigo em Inglês | IBECS | ID: ibc-177899

RESUMO

BACKGROUND: One of the loop diuretics, furosemide, was found useful in bronchial asthma. It enhanced anti-asthmatic effects of albuterol. The underlying mechanism is still unclear. OBJECTIVE: This study was planned to investigate whether the enhancing effect of furosemide for albuterol in ovalbumin-induced asthmatic BALB/c mice is diuretic-related or not. METHODS: Two sets of experiments were performed. In the first, effects of inhaled subdiuretic doses of furosemide and bumetanide (another loop diuretic) were compared. Treatments (mg/mL) were given as 15 minute-inhalation before final ovalbumin provocation as follows: albuterol (2.5), furosemide (0.08), bumetanide (0.005), (albuterol + furosemide, 2.5 + 0.08), and (albuterol+bumetanide, 2.5 + 0.005). Airway hyperreactivity (AHR) to inhaled methacholine, levels of IL-6, TNF-alfa, and differential white blood cells in bronchoalveolar lavage fluid (BALF), and lung histopathology were evaluated. In the second set, effects of oral diuretic doses (mg/kg) of furosemide (10) and bumetanide (0.25) were given before final ovalbumin provocation. Urine volume and asthma parameters were measured. RESULTS: Ovalbumin-asthmatic mice showed significant increases in AHR, levels of IL-6, TNF-alfa, and inflammatory cells in BALF, and lung inflammatory cell infiltration. Inhaled furosemide significantly decreased these changes while inhaled bumetanide failed. Albuterol and albuterol + bumetanide significantly decreased these changes more than furosemide while albuterol + furosemide produced the most significant decreases. Both oral furosemide and bumetanide exerted equivalent diuretic effects but failed to improve asthma. CONCLUSIONS: Inhaled subdiuretic dose of furosemide enhanced effects of albuterol more in ovalbumin-asthmatic mice rather than bumetanide, while oral diuretic doses of both drugs failed to improve asthma, indicating that this enhancing effect is not diuretic-related


No disponible


Assuntos
Humanos , Animais , Feminino , Camundongos , Albuterol/uso terapêutico , Asma/tratamento farmacológico , Bumetanida/uso terapêutico , Furosemida/uso terapêutico , Alérgenos/imunologia , Sinergismo Farmacológico , Quimioterapia Combinada , Interleucina-6/metabolismo , Pulmão/patologia , Camundongos Endogâmicos BALB C , Ovalbumina/imunologia , Fator de Necrose Tumoral alfa/metabolismo
15.
Ars pharm ; 58(2): 53-58, abr.-jun. 2017. tab
Artigo em Inglês | IBECS | ID: ibc-165308

RESUMO

Objectives: Argemone mexicana have been widely studied for its several pharmacological benefits and has been used in traditional medicine to treat constipation like symptoms. The present study carried out to evaluate the extract for its diuretic and laxative potential. Method: The aqueous extract of Argemone mexicana prepared using percolation method and subjected to phytochemical analysis. Evaluation of diuretic and laxative activity was carried out using metabolic cage apparatus and flame photometer as per the standard method reported earlier. Frusemide (20 mg/ kg) and sodium picosulate (5 mg/kg) were served as positive control for diuretic activity and laxative activity respectively. Result: The extract showed significant diuretic activity at 250 mg/kg dose when compared to standard frusemide. Even this extract also effective in increasing electrolyte concentration. Whereas the extract at 250 mg/kg showed significantly increasing in fecal output, and also significantly increased the weight of feces at 100 mg/kg and 200 mg/kg dose. Conclusion: The previous significant finding supports the traditional use of Argemone mexicana for its diuretic and laxative potential


Objetivos: Argemone mexicana ha sido ampliamente estudiada por sus diversos beneficios farmacológicos y se ha utilizado en la medicina tradicional para tratar síntomas de estreñimiento. El presente estudio evaluó el extracto por su potencial diurético y laxante. Método: El extracto acuoso de Argemone mexicana se preparó utilizando el método de percolación y se sometió a análisis fitoquímico. La evaluación de la actividad diurética y laxante se llevó a cabo utilizando unas jaulas metabólicas y un fotómetro de llama según el método estándar descrito con anterioridad. Se administró frusemida (20 mg / kg) y picosulato de sodio (5 mg / kg) como control positivo de la actividad diurética y actividad laxante respectivamente. Resultado: El extracto mostró una actividad diurética significativa a una dosis de 250 mg / kg en comparación con la frusemida estándar. Incluso, este extracto también es efectivo para aumentar la concentración de electrolitos. Mientras que el extracto a 250 mg/kg mostró un aumento significativo en la producción fecal, y también aumentó significativamente el peso de las heces en ambas dosis. Conclusión: El hallazgo significativo anterior apoya el uso tradicional de Argemone mexicana por sus potencialidades diurética y laxante


Assuntos
Animais , Ratos , Diuréticos/farmacocinética , Argemone , Extratos Vegetais/farmacocinética , Constipação Intestinal/tratamento farmacológico , Laxantes/farmacocinética , Medicamento Fitoterápico , Furosemida/uso terapêutico , Loperamida/uso terapêutico , Modelos Animais de Doenças
18.
Prog. obstet. ginecol. (Ed. impr.) ; 58(8): 363-367, oct. 2015. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-141296

RESUMO

La miocardiopatía periparto es una enfermedad con una elevada morbimortalidad y que, a pesar de sus riesgos potenciales, no es posible prevenirla. Por ello, solo podremos actuar sobre los factores de riesgo asociados a su aparición y sobre las complicaciones una vez diagnosticada. Debido a su baja incidencia, es difícil el conocimiento real de esta enfermedad, ya que se basa en artículos publicados sobre series reducidas de casos. El propósito de esta revisión es realizar una descripción de la fisiopatología, las manifestaciones clínicas, el diagnóstico y el tratamiento de la enfermedad, enfocada principalmente en el manejo obstétrico de la gestante (AU)


Peripartum cardiomyopathy is a serious disease with high morbidity and mortality. Despite its potential risks, prevention is not possible. Therefore, the only feasible strategy is to treat the risk factors and associated complications. Due to the low incidence of peripartum cardiomyopathy, is difficult to achieve real knowledge of this disease, which is based on small case series. This review aims to describe the pathophysiology, clinical manifestations, diagnosis and treatment of peripartum cardiomyopathy, with special emphasis on the obstetric management of pregnant women (AU)


Assuntos
Adulto , Feminino , Humanos , Gravidez , Cardiomiopatias/complicações , Cardiomiopatias , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca , Complicações na Gravidez , Fatores de Risco , Cesárea/métodos , Furosemida/uso terapêutico , Espironolactona/uso terapêutico , /uso terapêutico , Período Pós-Parto/fisiologia , Cardiomiopatias/fisiopatologia , Ruptura Prematura de Membranas Fetais/fisiopatologia , Ruptura Prematura de Membranas Fetais , Insuficiência da Valva Mitral/epidemiologia , Insuficiência da Valva Mitral/prevenção & controle , Radiografia Torácica/instrumentação , Radiografia Torácica/métodos , Radiografia Torácica , Imageamento por Ressonância Magnética/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...